Incannex Healthcare: Achieves interim milestone in psilocybin trial
Incannex Healthcare Achieves interim milestone in psilocybin trialIncannex Healthcare (IHL) achieves an interim milestone in its clinical trial to treat generalised anxiety disorder
...
Incannex Healthcare: Completes phase 2 clinical trial of IHL-42X
Incannex Healthcare Completes phase 2 clinical trial of IHL-42XIncannex Healthcare (IHL) completes the phase two trial of its cannabinoid combination drug IHL-42X
The...
Incannex Healthcare: Receives ethics approval for OSA trial
Incannex Healthcare has received ethics approval for a phase 2b clinical trial investigating its obstructive sleep apnoea (OSA) treatment
OSA occurs when the...
Incannex Healthcare: Expects record sales in June quarter
Incannex Healthcare: Expects record sales in June quarterIncannex Healthcare (IHL), formerly known as Impression Healthcare, expects to report $671,000 in cash sales receipts...

